Phenotypic Drug Discovery
An inherent challenge with cell-based assays is the development of bioanalytical techniques that preserve the intrinsic biological properties of the pathway or target being investigated. The use of labels (genomic and antibody based) can alter the physiology of the cells, thus affecting the outcome of the assay [1-2].
The stains, antibodies, and genetic labels currently used for phenotypic drug discovery can lead to biased decisions, artifacts, and erroneous results. It is thought that the use of labels in preclinical screening is one of the causes of drug failure in human clinical trials. Conversely, how many drug candidates were discarded based upon faulty data that could have been effective against human disease.
LumaCyte’s Radiance technology has the ability to evaluate phenotypic effects on cells without the use of labels.